These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 8652509)
41. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959 [TBL] [Abstract][Full Text] [Related]
42. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors. Chirgadze NY; Sall DJ; Briggs SL; Clawson DK; Zhang M; Smith GF; Schevitz RW Protein Sci; 2000 Jan; 9(1):29-36. PubMed ID: 10739244 [TBL] [Abstract][Full Text] [Related]
43. Prostaglandin H synthase: perturbation of the tyrosyl radical as a probe of anticyclooxygenase agents. Kulmacz RJ; Palmer G; Tsai AL Mol Pharmacol; 1991 Nov; 40(5):833-7. PubMed ID: 1658613 [TBL] [Abstract][Full Text] [Related]
44. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. Kulmacz RJ; Lands WE J Biol Chem; 1985 Oct; 260(23):12572-8. PubMed ID: 3930499 [TBL] [Abstract][Full Text] [Related]
45. The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. Rieke CJ; Mulichak AM; Garavito RM; Smith WL J Biol Chem; 1999 Jun; 274(24):17109-14. PubMed ID: 10358065 [TBL] [Abstract][Full Text] [Related]
46. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. DeWitt DL; Meade EA; Smith WL Am J Med; 1993 Aug; 95(2A):40S-44S. PubMed ID: 8357002 [TBL] [Abstract][Full Text] [Related]
47. The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. Callan OH; So OY; Swinney DC J Biol Chem; 1996 Feb; 271(7):3548-54. PubMed ID: 8631960 [TBL] [Abstract][Full Text] [Related]
48. Experience with the particulate prostaglandin endoperoxide synthase assay for testing non-steroidal antiinflammatory drugs. Schewe C; Ludwig P; Holzhütter HG; Schewe T Pharmazie; 1991 Nov; 46(11):804-9. PubMed ID: 1811233 [TBL] [Abstract][Full Text] [Related]
49. The structures of prostaglandin endoperoxide H synthases-1 and -2. Garavito RM; Malkowski MG; DeWitt DL Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():129-52. PubMed ID: 12432914 [TBL] [Abstract][Full Text] [Related]
50. Profiling the interaction of 1-phenylbenzimidazoles to cyclooxygenases. Gómez-Castro CZ; López-Martínez M; Hernández-Pineda J; Trujillo-Ferrara JG; Padilla-Martínez II J Mol Recognit; 2019 Nov; 32(11):e2801. PubMed ID: 31353677 [TBL] [Abstract][Full Text] [Related]
51. The structural and electronical factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates. Pouplana R; Pérez C; Sánchez J; Lozano JJ; Puig-Parellada P J Comput Aided Mol Des; 1999 May; 13(3):297-313. PubMed ID: 10216835 [TBL] [Abstract][Full Text] [Related]
52. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis. Ermondi G; Caron G; Lawrence R; Longo D J Comput Aided Mol Des; 2004 Nov; 18(11):683-96. PubMed ID: 15865061 [TBL] [Abstract][Full Text] [Related]
53. Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2). Filizola M; Perez JJ; Palomer A; Mauleón D J Mol Graph Model; 1997 Oct; 15(5):290-300. PubMed ID: 9640560 [TBL] [Abstract][Full Text] [Related]
54. Bromoacetamido-analogs of indomethacin and mefenamic acid affinity-label prostaglandin H2 synthase at two sites. Tang MS; Askonas LJ; Penning TM Adv Exp Med Biol; 1997; 400A():77-84. PubMed ID: 9547540 [No Abstract] [Full Text] [Related]
55. Dynamics of different arachidonic acid orientations bound to prostaglandin endoperoxide synthases. Sachett LG; Verli H Eur J Med Chem; 2011 Oct; 46(10):5212-7. PubMed ID: 21864948 [TBL] [Abstract][Full Text] [Related]
56. Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals the presence of the new common ligand-binding site. Singh N; Kumar RP; Kumar S; Sharma S; Mir R; Kaur P; Srinivasan A; Singh TP J Mol Recognit; 2009; 22(6):437-45. PubMed ID: 19462410 [TBL] [Abstract][Full Text] [Related]
57. Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs). Dwivedi AK; Gurjar V; Kumar S; Singh N Drug Discov Today; 2015 Jul; 20(7):863-73. PubMed ID: 25794602 [TBL] [Abstract][Full Text] [Related]
58. Differential binding mode of diverse cyclooxygenase inhibitors. Llorens O; Perez JJ; Palomer A; Mauleon D J Mol Graph Model; 2002 Mar; 20(5):359-71. PubMed ID: 11885959 [TBL] [Abstract][Full Text] [Related]
59. Peroxidase self-inactivation in prostaglandin H synthase-1 pretreated with cyclooxygenase inhibitors or substituted with mangano protoporphyrin IX. Wu G; Vuletich JL; Kulmacz RJ; Osawa Y; Tsai AL J Biol Chem; 2001 Jun; 276(23):19879-88. PubMed ID: 11279106 [TBL] [Abstract][Full Text] [Related]
60. Anchoring of a monotopic membrane protein: the binding of prostaglandin H2 synthase-1 to the surface of a phospholipid bilayer. Nina M; Bernèche S; Roux B Eur Biophys J; 2000; 29(6):439-54. PubMed ID: 11081405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]